What is the breakthrough?
For the first time in history, doctors have dramatically slowed the progression of Huntington’s disease through gene therapy. In a groundbreaking clinical trial, researchers at University College London reported that the therapy reduced disease progression by 75%, offering hope to patients and families facing this devastating genetic disorder.
Professor Sarah Tabrizi, who led the study, called the results “spectacular.” Patients who would normally experience one year of neurological decline now show the same level of progression over four years, potentially extending both life expectancy and quality of life.
How does the gene therapy work?
The treatment combines advanced gene-editing techniques with complex neurosurgery:
- Procedure length: The surgery lasts up to 18 hours.
- Delivery method: Doctors implant a specially designed DNA sequence deep into the brain.
- Goal: The DNA sequence suppresses production of the toxic huntingtin protein, which is responsible for destroying brain cells in Huntington’s patients.
- Real-time guidance: MRI scans guide surgeons during the delicate process, ensuring the therapy reaches critical brain regions.
By reducing the toxic protein, the therapy protects neurons and stabilizes brain function.
What is Huntington’s disease?
Huntington’s disease is a hereditary neurological disorder caused by a mutation in the huntingtin gene.
- Inheritance risk: A child of an affected parent has a 50% chance of inheriting the faulty gene.
- Age of onset: Symptoms usually appear in a patient’s 30s or 40s.
- Symptoms:
- Uncontrolled movements and muscle problems
- Severe cognitive decline
- Psychiatric disturbances, including depression and aggression
- Prognosis: The disease is usually fatal within 10–20 years of onset.
Until now, no treatment could slow or stop the progression of the disease.
What did the trial show?
The clinical trial involved 29 patients, and the results were striking:
- Disease progression slowed by 75% compared to the normal course.
- Patients maintained better motor skills, cognitive function, and daily living abilities.
- Neurofilament levels (a marker of nerve cell death) remained stable or improved, instead of rising as expected.
These findings suggest the therapy not only slows decline but also helps preserve brain cells.
What are the challenges?
While groundbreaking, the therapy faces several obstacles:
- High complexity: The procedure requires lengthy, highly specialized brain surgery.
- Cost barrier: Like most gene therapies, it is extremely expensive. For comparison, the UK’s National Health Service (NHS) currently funds a hemophilia B gene therapy priced at £2.6 million per patient.
- Accessibility: Without significant investment and scaling, only a small number of patients will be able to access treatment in the near future.
Professor Ed Wild, a consultant neurologist on the team, noted that while costly upfront, the long-term benefits could make it more economical compared to decades of palliative care.
What’s next for this therapy?
Researchers are already planning larger trials and preventative studies for individuals who carry the mutation but have not yet shown symptoms. If proven effective earlier in life, the therapy could change the outlook for future generations at risk of Huntington’s.
Still, major questions remain:
- Can the therapy be delivered at scale?
- Will insurers and health systems cover the costs?
- Could the same approach be adapted for other neurodegenerative conditions, such as ALS or Alzheimer’s?
Why this matters beyond Huntington’s
This therapy marks the start of a new era in genetic medicine. Huntington’s has long been viewed as a relentless, untreatable condition. By showing that gene therapy can dramatically slow its progression, researchers have opened the door to similar strategies for other incurable brain diseases.
The implications stretch beyond Huntington’s: this is a proof of principle that editing or silencing harmful genes in the brain is possible and effective.
TL;DR
Scientists have slowed Huntington’s disease progression by 75% using experimental gene therapy. The treatment, delivered via complex brain surgery, suppresses the toxic protein that causes nerve cell death. While costs and surgical complexity remain challenges, the breakthrough offers hope for longer, higher-quality lives and could pave the way for future therapies against neurodegenerative diseases.